155 related articles for article (PubMed ID: 17329907)
1. Theory based analysis of anti-inflammatory effect of infliximab on Crohn's disease.
Furuya Y; Ozeki T; Takayanagi R; Yokoyama H; Okuyama K; Yamada Y
Drug Metab Pharmacokinet; 2007 Feb; 22(1):20-5. PubMed ID: 17329907
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial.
Buhl SS; Steenholdt C; Brynskov J; Thomsen OØ; Bendtzen K; Ainsworth MA
BMJ Open; 2014 Dec; 4(12):e005887. PubMed ID: 25524543
[TBL] [Abstract][Full Text] [Related]
3. Theory-based analysis of anti-inflammatory effect of infliximab on Crohn's disease and rheumatoid arthritis.
Kimura K; Takayanagi R; Yokoyama H; Yamada Y
Rheumatol Int; 2012 Jan; 32(1):145-50. PubMed ID: 20680285
[TBL] [Abstract][Full Text] [Related]
4. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.
Steenholdt C; Brynskov J; Thomsen OØ; Munck LK; Fallingborg J; Christensen LA; Pedersen G; Kjeldsen J; Jacobsen BA; Oxholm AS; Kjellberg J; Bendtzen K; Ainsworth MA
Gut; 2014 Jun; 63(6):919-27. PubMed ID: 23878167
[TBL] [Abstract][Full Text] [Related]
5. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease.
Steenholdt C
Dan Med J; 2013 Apr; 60(4):B4616. PubMed ID: 23651723
[TBL] [Abstract][Full Text] [Related]
6. Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial.
Yoshida K; Fukunaga K; Ikeuchi H; Kamikozuru K; Hida N; Ohda Y; Yokoyama Y; Iimuro M; Takeda N; Kato K; Kikuyama R; Nagase K; Hori K; Nakamura S; Miwa H; Matsumoto T
Inflamm Bowel Dis; 2012 Sep; 18(9):1617-23. PubMed ID: 22081474
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents.
Kestens C; van Oijen MG; Mulder CL; van Bodegraven AA; Dijkstra G; de Jong D; Ponsioen C; van Tuyl BA; Siersema PD; Fidder HH; Oldenburg B;
Clin Gastroenterol Hepatol; 2013 Jul; 11(7):826-31. PubMed ID: 23376000
[TBL] [Abstract][Full Text] [Related]
8. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF.
Yamada A; Sono K; Hosoe N; Takada N; Suzuki Y
Inflamm Bowel Dis; 2010 Nov; 16(11):1898-904. PubMed ID: 20310016
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of treatment with chimeric monoclonal antibody (Infliximab) to tumor necrosis factor-alpha for Crohn's disease in Japan: evaluation by rapid turnover proteins, and radiologic and endoscopic findings.
Asakura H; Yao T; Matsui T; Koganei K; Fukushima T; Takazoe M; Hobara R; Nakano H; Okamura S; Matsueda K; Kashida H; Makiyama K; Hiwatashi N; Kashiwagi K; Hibi T
J Gastroenterol Hepatol; 2001 Jul; 16(7):763-9. PubMed ID: 11446884
[TBL] [Abstract][Full Text] [Related]
10. Transcending conventional therapies: the role of biologic and other novel therapies.
Sandborn WJ
Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S9-16. PubMed ID: 11380043
[TBL] [Abstract][Full Text] [Related]
11. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
Gisbert JP; Marín AC; McNicholl AG; Chaparro M
Aliment Pharmacol Ther; 2015 Apr; 41(7):613-23. PubMed ID: 25652884
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease.
Narula N; Kainz S; Petritsch W; Haas T; Feichtenschlager T; Novacek G; Eser A; Vogelsang H; Reinisch W; Papay P
Aliment Pharmacol Ther; 2016 Jul; 44(2):170-80. PubMed ID: 27226407
[TBL] [Abstract][Full Text] [Related]
13. Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn's disease: a cost-effectiveness analysis.
Saito S; Shimizu U; Nan Z; Mandai N; Yokoyama J; Terajima K; Akazawa K
J Crohns Colitis; 2013 Mar; 7(2):167-74. PubMed ID: 22626508
[TBL] [Abstract][Full Text] [Related]
14. Anti-TNF Therapy Induces CD4+ T-Cell Production of IL-22 and Promotes Epithelial Repairs in Patients With Crohn's Disease.
Fang L; Pang Z; Shu W; Wu W; Sun M; Cong Y; Liu Z
Inflamm Bowel Dis; 2018 Jul; 24(8):1733-1744. PubMed ID: 29718341
[TBL] [Abstract][Full Text] [Related]
15. Elective switching from infliximab to adalimumab in stable Crohn's disease.
Hoentjen F; Haarhuis BJ; Drenth JP; de Jong DJ
Inflamm Bowel Dis; 2013; 19(4):761-6. PubMed ID: 23446337
[TBL] [Abstract][Full Text] [Related]
16. The role of oxidative stress in anti-tumor necrosis factor antibody treatment in Crohn's disease.
Kupčova V; Tureckỳ L; Uhlíkova E
Curr Med Chem; 2012; 19(30):5226-31. PubMed ID: 23061628
[TBL] [Abstract][Full Text] [Related]
17. Prediction of clinical effects of infliximab administered for inflammatory bowel disease based on pharmacokinetic and pharmacodynamic modeling.
Kimura K; Yoshida A; Katagiri F; Takayanagi R; Yamada Y
Biopharm Drug Dispos; 2019 Jul; 40(7):250-261. PubMed ID: 31256430
[TBL] [Abstract][Full Text] [Related]
18. [Anti-TNF therapy in treatment of luminal Crohn's disease].
Marko B; Prka L
Acta Med Croatica; 2013 Apr; 67(2):179-89. PubMed ID: 24471301
[TBL] [Abstract][Full Text] [Related]
19. Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohn's Disease.
Stein R; Lee D; Leonard MB; Thayu M; Denson LA; Chuang E; Herskovitz R; Kerbowski T; Baldassano RN
Inflamm Bowel Dis; 2016 Jun; 22(6):1370-7. PubMed ID: 27057683
[TBL] [Abstract][Full Text] [Related]
20. Infliximab reverses inflammatory muscle wasting (sarcopenia) in Crohn's disease.
Subramaniam K; Fallon K; Ruut T; Lane D; McKay R; Shadbolt B; Ang S; Cook M; Platten J; Pavli P; Taupin D
Aliment Pharmacol Ther; 2015 Mar; 41(5):419-28. PubMed ID: 25580985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
